These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18549914)

  • 21. Uric acid, xanthine oxidase and heart failure: unresolved issues.
    Verdejo H; Alcaino H; Greig D; Garcia L; Pizarro M; Chiong M; Castro P; Lavandero S
    Eur J Heart Fail; 2008 Dec; 10(12):1271-2. PubMed ID: 19010082
    [No Abstract]   [Full Text] [Related]  

  • 22. Can Xanthine Oxidase Inhibitors Improve Cardiac Function in Patients With Chronic Heart Failure?
    Sugihara S; Yamamoto K; Hisatome I
    Int Heart J; 2016 Dec; 57(6):661-662. PubMed ID: 27818485
    [No Abstract]   [Full Text] [Related]  

  • 23. The year in heart failure.
    Tang WH; Francis GS
    J Am Coll Cardiol; 2005 Dec; 46(11):2125-33. PubMed ID: 16325052
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biomarkers in heart failure: are they clinically useful?].
    Kempf T; Wollert KC
    Dtsch Med Wochenschr; 2009 Apr; 134(15):740-6. PubMed ID: 19340752
    [No Abstract]   [Full Text] [Related]  

  • 25. [The role of uric acid in heart failure].
    Alcaíno H; Greig D; Castro P; Verdejo H; Mellado R; García L; Díaz-Araya G; Quiroga C; Chiong M; Lavandero S
    Rev Med Chil; 2011 Apr; 139(4):505-15. PubMed ID: 21879191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uric acid in CHF: marker or player in a metabolic disease?
    Doehner W; von Haehling S; Anker SD
    Int J Cardiol; 2007 Feb; 115(2):156-8. PubMed ID: 16844250
    [No Abstract]   [Full Text] [Related]  

  • 27. Allopurinol treatment reduces arterial wave reflection in stroke survivors.
    Khan F; George J; Wong K; McSwiggan S; Struthers AD; Belch JJ
    Cardiovasc Ther; 2008; 26(4):247-52. PubMed ID: 19035875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous electrochemical monitoring of metabolites related to the xanthine oxidase pathway using a grinded carbon electrode.
    Hason S; Stepankova S; Kourilova A; Vetterl V; Lata J; Fojta M; Jelen F
    Anal Chem; 2009 Jun; 81(11):4302-7. PubMed ID: 19402672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of b-type natriuretic peptide in heart failure management.
    Newton PJ; Betihavas V; Macdonald P
    Aust Crit Care; 2009 Aug; 22(3):117-23. PubMed ID: 19589695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperuricaemia and congestive heart failure: causation or association?
    Gottlieb S
    Eur Heart J; 1998 Dec; 19(12):1746-7. PubMed ID: 9886713
    [No Abstract]   [Full Text] [Related]  

  • 32. Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure?
    Gao LG; Yao XP; Zhang L; Wen D; Luo F; Zhou XL; Hui RT
    Chin Med J (Engl); 2010 Sep; 123(17):2471-4. PubMed ID: 21034568
    [No Abstract]   [Full Text] [Related]  

  • 33. Diagnostic and prognostic value of uric acid in patients with acute dyspnea.
    Reichlin T; Potocki M; Breidthardt T; Noveanu M; Hartwiger S; Burri E; Klima T; Stelzig C; Laule K; Mebazaa A; Christ M; Mueller C
    Am J Med; 2009 Nov; 122(11):1054.e7-1054.e14. PubMed ID: 19854335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.
    Felker GM; Hasselblad V; Hernandez AF; O'Connor CM
    Am Heart J; 2009 Sep; 158(3):422-30. PubMed ID: 19699866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers.
    Lainscak M; von Haehling S; Anker SD
    Int J Cardiol; 2009 Mar; 132(3):303-11. PubMed ID: 19144431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interpretation of amino-terminal pro-brain natriuretic peptide levels in the HPS and the CORONA study.
    Cleland JG; Squire I; Ng L
    J Am Coll Cardiol; 2008 Sep; 52(13):1104-5. PubMed ID: 18848145
    [No Abstract]   [Full Text] [Related]  

  • 37. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis.
    Maisel AS; Peacock WF; McMullin N; Jessie R; Fonarow GC; Wynne J; Mills RM
    J Am Coll Cardiol; 2008 Aug; 52(7):534-40. PubMed ID: 18687247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uric acid in chronic heart failure--current pathophysiological concepts.
    Doehner W; Springer J; Landmesser U; Struthers AD; Anker SD
    Eur J Heart Fail; 2008 Dec; 10(12):1269-70. PubMed ID: 19008148
    [No Abstract]   [Full Text] [Related]  

  • 39. [Tailored drug therapy in heart failure--a future vision. Biological markers can support individually directed treatment].
    Dahlström U
    Lakartidningen; 2009 Oct 14-20; 106(42):2674-5. PubMed ID: 19967945
    [No Abstract]   [Full Text] [Related]  

  • 40. Lonicera hypoglauca inhibits xanthine oxidase and reduces serum uric acid in mice.
    Chien SC; Yang CW; Tseng YH; Tsay HS; Kuo YH; Wang SY
    Planta Med; 2009 Mar; 75(4):302-6. PubMed ID: 19184967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.